In situ floating hydrogel for intravesical delivery of adriamycin without blocking urinary tract

Journal of Pharmaceutical Sciences

Volumn 103, Issue 3, 2014, Pages 927-936

  Lin, Tingsheng ^a,b   Wu, Jinhui ^a   Zhao, Xiaozhi ^b   Lian, Huibo ^b   Yuan, Ahu ^a   Tang, Xiaolei ^a   Zhao, Sai ^a   Guo, Hongqian ^b   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

biodegradable polymers; cancer chemotherapy; controlled release; drug delivery systems; intravesical instillation; thermal gels

Indexed keywords

DOXORUBICIN; POLYMER; ALB PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; BICARBONATE; BIODEGRADABLE PLASTIC; DELAYED RELEASE FORMULATION; HYDROGEL; POLOXAMER; PROTECTIVE AGENT; SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FEMALE; GEL; HEAT SENSITIVITY; HIGH TEMPERATURE; HYDROGEL; LIQUID; LOW TEMPERATURE; NONHUMAN; RAT; URINALYSIS; URINARY TRACT; ANIMAL; BLADDER; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; INTRAVESICAL DRUG ADMINISTRATION; METABOLISM; PROTEIN FOLDING; RANDOMIZATION; RELATIVE DENSITY; SOLUBILITY; TISSUE DISTRIBUTION; URETHRAL OBSTRUCTION; URINE; WISTAR RAT;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIODEGRADABLE PLASTICS; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG COMPOUNDING; FEMALE; HYDROGELS; POLOXAMER; PROTECTIVE AGENTS; PROTEIN FOLDING; RANDOM ALLOCATION; RATS; RATS, WISTAR; SERUM ALBUMIN; SODIUM BICARBONATE; SOLUBILITY; SPECIFIC GRAVITY; TISSUE DISTRIBUTION; URETHRAL OBSTRUCTION; URINARY BLADDER;

EID: 84894493071     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23854     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. 2011. Global cancer statistics. CA Cancer J Clin 61 (2): 69-90.
2. Kurth K, Bouffioux C, Sylvester R, Van der Meijden A, Oosterlinck W, Brausi M,. 2000. Treatment of superficial bladder tumors: Achievements and needs. Eur Urol 37 (Suppl. 3): 1-9.
3. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL-S,. 2008. Intravesical treatments of bladder cancer: Review. Pharm Res 25 (7): 1500-1510.
4. Jeong B, Kim SW, Bae YH,. 2012. Thermosensitive sol-gel reversible hydrogels. Adv Drug Deliv Rev 64 (Suppl): 154-162.
5. Xu K, Wang L, Qiang M, Wang L, Li P, Tang B,. 2011. A selective near-infrared fluorescent probe for singlet oxygen in living cells. Chem Commun 47 (26): 7386-7388.
6. Wang P, Johnston T,. 1991. Kinetics of sol to gel transition for poloxamer polyols. J Appl Polym Sci 43 (2): 283-292.
7. Alexandridis P, Alan Hatton T,. 1995. Poly (ethylene oxide) poly (propylene oxide) poly (ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: Thermodynamics, structure, dynamics, and modeling. Colloids Surf A: Physicochem Eng Asp 96 (1): 1-46.
8. Mortensen K, Pedersen JS,. 1993. Structural study on the micelle formation of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) triblock copolymer in aqueous solution. Macromolecules 26 (4): 805-812.
9. Oki T., 1977. New anthracycline antibiotics. Jpn J Antibiot 30: 70.
10. Dalbagni G., 2007. The management of superficial bladder cancer. Nat Clin Pract Urol 4 (5): 254-260.
11. Eto H, Oka Y, Ueno K, Nakamura I, Yoshimura K, Arakawa S, Kamidono S, Obe S, Ogawa T, Hamami G,. 1994. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: A multicenter randomized trial. Cancer Chemother Pharmacol 35 (1): S46-S51.
12. Yuan A, Wu J, Song C, Tang X, Qiao Q, Zhao L, Gong G, Hu Y,. 2013. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity. J Pharm Sci 102 (5): 1626-1635.
13. Abrams P, Choa R, Gaches C, Ashken M, Green N,. 1981. A controlled trial of single dose intravesical Adriamycin in superficial bladder tumours. Br J Urol 53 (6): 585-587.
14. Costa P, Sousa Lobo JM,. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13 (2): 123-133.
15. Walsh S, Shirley D, Wrong O, Unwin R,. 2007. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: An alternative to ammonium chloride. Kidney Int 71 (12): 1310-1316.
16. Paavola A, Kilpeläinen I, Yliruusi J, Rosenberg P,. 2000. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm 199 (1): 85-93.
17. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC,. 2006. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 23 (12): 2709-2728.
18. Ricci E, Lunardi L, Nanclares D, Marchetti J,. 2005. Sustained release of lidocaine from Poloxamer 407 gels. Int J Pharm 288 (2): 235-244.
19. Zhang L, Parsons DL, Navarre C, Kompella UB,. 2002. Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85 (1): 73-81.
20. Singh BN, Kim KH,. 2000. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release 63 (3): 235-259.
21. Prajapati VD, Jani GK, Khutliwala TA, Zala BS,. 2013. Raft forming system-an upcoming approach of gastroretentive drug delivery system. J Control Release 168 (2): 151-165.
22. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT,. 2011. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. Drug Deliv 18 (2): 97-110.
23. Xu X, Sun M, Zhi F, Hu Y,. 2006. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: In vitro and in vivo evaluation in healthy volunteers. Int J Pharm 310 (1): 139-145.
24. Geny B, Mettauer B, Muan B, Bischoff P, Epailly E, Piquard F, Eisenmann B, Haberey P,. 1993. Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients. J Am Coll Cardiol 22 (4): 1193-1198.
25. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J,. 1999. Significant transport of doxorubicin into the f brain with polysorbate 80-coated nanoparticles. Pharm Res 16 (10): 1564-1569.